Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will (a) publish a strategy to help improve the (i) diagnosis and (ii) detection of less survivable cancers and (b) ensure comprehensive (A) commissioning and (B) diagnostic capacity in (1) non-specific symptoms pathways, (2) urgent suspected cancer pathways and (3) GP direct access.

The Department is working to develop a new National Cancer Plan, which will include further details on how we will improve the diagnosis and detection of less survivable cancers.

As set out in the new plan for reforming elective care, the Government is committed to improving diagnostic capacity for cancer patients. Providers have been asked to identify local opportunities in both community diagnostic centres (CDCs) and hospital based diagnostic services to improve performance against the NHS Constitution standard for diagnostics and the cancer faster diagnosis standard, to reduce the number of patients waiting too long for a confirmed diagnosis of cancer and to start treatment.

The 2025/26 capital guidance confirmed that £1.65 billion of capital funding will be allocated to support National Health Service performance across secondary and emergency care across 2025/26 more broadly. This includes £0.6 billion which has been provisionally allocated for interventions to increase diagnostic capacity, including expanding existing CDCs, as well as building up to five new CDCs in 2025/26.

To expand diagnostic capacity in the non-specific symptom pathway (NSS), the NHS is rolling out rapid diagnostic centres (RDC) as part of the NSS pathway, where patients suspected of having cancer can get the right tests at the right time in as few visits as possible. RDC pathways promote the continuous improvement of cancer diagnostics.

The NHS is also expanding direct access to diagnostic scans across all general practices through the national roll out of fast track testing, helping to cut waiting times and speed up cancer diagnosis or cancer all-clear for patients, including developing and delivering at least 10 straight-to-test pathways by March 2026.